Esperion Therapeutics, a developer of small molecule therapies for the treatment of cardiometabolic disorders, has appointed Tim Mayleben as president and CEO. Founder Roger Newton, who formerly held these positions, will become executive chairman and chief scientific officer.
Most recently, Mayleben was president and CEO of Aastrom Biosciences. Prior to this he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors, and president, COO and a director of NightHawk Radiology. He was also chief operating officer and CFO of the original Esperion Therapeutics, which Newton also founded. While at Esperion, Mayleben raised more than US$200m in venture and institutional equity capital and negotiated the sale of the company to Pfizer for $1.3bn in February 2004.
‘We've made tremendous progress with ETC-1002, our novel small molecule LDL-C lowering therapy for treating statin-intolerant and statin-resistant patients,’ said Newton. ‘I'm excited that Tim is re-joining me at the new Esperion. He's the ideal person to help guide Esperion through the next phases of our growth and development. At the original Esperion, Tim's outstanding business acumen and judgment played a critical role in our success at every stage.’
ETC-1002 is in Phase II clinical trials for patients with hypercholesterolemia and other cardiometabolic risk factors. It is being developed to address the underlying causes of metabolic diseases and reduce multiple risk factors associated with them.